Cellular Biomedicine Group, Inc. (CBMG) financial statements (2022 and earlier)

Company profile

Business Address 209 PERRY PARKWAY
GAITHERSBURG, MD 20877
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15,44452,81321,56839,25214,88514,771
Cash and cash equivalents15,44452,81321,56839,25214,88514,771
Restricted cash and investments17,000     
Receivables 120340780141
Inventory, net of allowances, customer advances and progress billings    391372
Inventory    391372
Intangible current assets     11,157
Other current assets     110
Other undisclosed current assets1,5861,7942,7561,400638(10,455)
Total current assets:34,03054,60824,52740,69216,69416,095
Noncurrent Assets
Operating lease, right-of-use asset20,106
Property, plant and equipment21,43415,19412,9734,1182,7691,280
Long-term investments and receivables2402402695095,3796,886
Long-term investments2402402695095,3796,886
Intangible assets, net (including goodwill)7,6797,6797,6797,6797,67918,835
Goodwill7,6797,6797,6797,6797,6797,679
Intangible assets, net (excluding goodwill)     11,157
Other undisclosed noncurrent assets13,83513,92315,71415,63016,939588
Total noncurrent assets:63,29537,03536,63527,93632,76627,590
TOTAL ASSETS:97,32491,64361,16268,62849,46043,685
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,9712,3311,3511,4141,1063,316
Accounts payable2,040423225216261427
Accrued liabilities1,9051,8791,0971,1698452,074
Taxes payable26292929 814
Debt14,334     
Due to related parties     36
Other liabilities5,3683,8362,3259501,913724
Total current liabilities:23,6736,1673,6762,3643,0194,076
Noncurrent Liabilities
Liabilities, other than long-term debt17,93425818437076453
Accounts payable and accrued liabilities 25818437076453
Other liabilities17,934     
Total noncurrent liabilities:17,93425818437076453
Total liabilities:41,6076,4253,8602,7353,0954,529
Stockholders' equity
Stockholders' equity attributable to parent55,71885,21857,30365,89446,36539,156
Common stock201916141211
Treasury stock, value(14,993)(13,954)(3,978)   
Additional paid in capital272,118250,605172,691152,543103,80875,467
Accumulated other comprehensive income (loss)(1,461)(1,469)(390)(1,117)(116)1,568
Accumulated deficit(199,967)(149,982)(111,037)(85,547)(57,338)(37,891)
Total stockholders' equity:55,71885,21857,30365,89446,36539,156
TOTAL LIABILITIES AND EQUITY:97,32491,64361,16268,62849,46043,685

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues3402242,4146282,505558
Revenue, net3376282,505564
Operating lease, lease income2,810
Other income6711,1202,077  
Cost of revenue(62)(136)(162)(745)(2,004)(213)
Cost of goods and services sold  (162)(745)(2,004)(213)
Other undisclosed gross profit  (2,077)(115)124 
Gross profit:27889175(232)625345
Operating expenses(51,332)(40,730)(27,913)(29,043)(23,354)(13,007)
Other undisclosed operating income621361628601,880219
Operating loss:(50,992)(40,506)(27,577)(28,415)(20,849)(12,442)
Nonoperating income1,0091,5652,08921167387
Other nonoperating income1991,1731,95513263072
Interest and debt expense(482)     
Loss from continuing operations before equity method investments, income taxes:(50,465)(38,941)(25,488)(28,204)(20,176)(12,355)
Other undisclosed income from continuing operations before income taxes482     
Loss from continuing operations before income taxes:(49,983)(38,941)(25,488)(28,204)(20,176)(12,355)
Income tax expense (benefit)(1)(5)(2)4(729)(51)
Loss from continuing operations:(49,984)(38,945)(25,490)(28,200)(20,905)(12,406)
Loss from discontinued operations     (3,119)
Net loss:(49,984)(38,945)(25,490)(28,200)(20,905)(15,525)
Other undisclosed net income (loss) attributable to parent   (8)1,45751
Net loss available to common stockholders, diluted:(49,984)(38,945)(25,490)(28,208)(19,448)(15,475)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(49,984)(38,945)(25,490)(28,200)(20,905)(15,525)
Other comprehensive income (loss)8(1,080)967(743)(308)15
Comprehensive loss:(49,976)(40,025)(24,523)(28,943)(21,213)(15,510)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (240)(265)811,662
Comprehensive loss, net of tax, attributable to parent:(49,976)(40,025)(24,763)(29,209)(21,132)(13,848)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: